
Doucet
The Doucet group is one of France’s leading manufacturers of homecare, insecticide and staining products for businesses and consumers (Starwax, Kapo, Kiraviv and Purodor brands, sold predominantly in DIY superstores and drugstores).
The Doucet group is one of France’s leading manufacturers of homecare, insecticide and staining products for businesses and consumers (Starwax, Kapo, Kiraviv and Purodor brands, sold predominantly in DIY superstores and drugstores).
Established in La Jumellière (Maine-et-Loire department) since 1982, Sogal is one of France’s leading manufacturers of made-to-measure wardrobes, sliding doors and walk-in wardrobes.
For the past ten years, Ocean has offered business intelligence solutions that maximise the efficiency of operational, administrative and financial management for both large groups and SMEs/micro-companies to bolster their development. Reports and charts available in real time facilitate decision-making and unlock concrete and quantifiable benefits.
Founded in 1921, the Dirickx group is an international specialist in perimeter protection for sites offering a wide range of products and services for boundaries, entrances, access control and management, and security.
Bizanga, a specialist in email management, sold its IMP (Intelligent Message Processor) email traffic management platform to US partner Cloudmark. Bizanga retains its storage business and has changed its name to Bizanga Store.
Software solutions for banks focused in particular on combating money-laundering. The sale to Swiss software vendor Temenos was among the largest deals in the European software vendor market in 2009.
Tonnellerie Saury joined the Charlois group, a family of stave producers for six generations, in December 2009. Production from the Charlois group’s two stave mills gives Tonnellerie Saury access to very high quality staves and ensures complete integration of the production chain.
Dutch company specialised in the clinical development of therapeutic antibodies. The company sold exclusive rights to its PG-110 antibody to Abbott for $190 million. Developed by PanGenetics, PG-110 is a humanised antibody targeting nerve growth factor (in phase I clinical trials). To date, the company has raised close to €51 million in the three funding rounds completed between 2005 and 2008. The deal is an endorsement of the company’s novel strategy predicated on the development of proprietary products and the licensing of new products, excluding R&D activities.
Founded in 2005 to break new ground in the treatment of retinal conditions, Fovea Pharmaceuticals has built an R&D portfolio covering ocular conditions with unmet needs, and now forms Sanofi’s Ophthalmology division. Its core approach is to put patients at the heart of its strategy, thanks to its presence at the Institut de la Vision located on the Quinze-Vingts hospital campus. Its team consists almost exclusively of research scientists.
The company was bought by Sanofi Aventis in 2009 in a deal worth up to €370 million.
Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.